Market Overview

UPDATE: Bank of America Reiterates Buy Rating, Raises PT on Mylan on Announced Agila Acquisition

Related MYL
Mylan Wins Motion For Temporary Restraining Order Against Apotex For Authorized Generic Of Paxil CR
Mylan Wins Motion To Enjoin GlaxoSmithKline From Providing Paroxetine CR Yo Apotex; Apotex Can No Longer Supply Authorized Generic Product
Will Congress Scuttle the AbbVie-Shire Merger? (Fox Business)

In a report published Monday, Bank of America reiterated its Buy rating on Mylan (NASDAQ: MYL), and slightly raised its price target from $33.00 to $34.00.

Bank of America noted, “On 2/27, MYL announced that it is buying Strides' injectables unit, Agila, for $1.6bn in cash. Our initial attempt at adding Agila to our MYL model generally validates MYL's assumption that the deal could be accretive quickly. Our new 2014/15E adj. EPS are $3.52/$3.50 vs. $3.38/$3.33 (or accretion of 4%/5%), and we are tweaking our DCF-based PO up to $34 (from $33). As we stated, we see this transaction as an exciting platform (existing products + pipeline) for MYL to dramatically accelerate its position in the strategically important injectables space, which has seen some FDA-related missteps by competitors (HSP, Ben Venue, TEVA, etc.), especially in the US.”

Mylan closed on Friday at $30.10.

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (MYL)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters